Chengdu Kanghong Pharmaceuticals Group saw no growth in patent filings and highest growth of 0.24% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.24%. GlobalData’s DataBook provides a comprehensive analysis of Chengdu Kanghong Pharmaceuticals Group’s patent filings and grants. Buy the databook here.
Chengdu Kanghong Pharmaceuticals Group has been focused on protecting inventions in China(CN) with one publication in Q2 2024
The China(CN) Patent Office dominates the patent filings with nearly 100% of filings. The China(CN), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Chengdu Kanghong Pharmaceuticals Group is filings its patents. Among the top granted patent authorities, Chengdu Kanghong Pharmaceuticals Group has 100% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Chengdu Kanghong Pharmaceuticals Group
Diabetic macular edema related patents lead Chengdu Kanghong Pharmaceuticals Group portfolio followed by diabetic retinopathy, and corneal neovascularization
Chengdu Kanghong Pharmaceuticals Group has highest number of patents in diabetic macular edema followed by diabetic retinopathy, corneal neovascularization, age related macular degeneration, and branch retinal vein occlusion.
For comprehensive analysis of Chengdu Kanghong Pharmaceuticals Group's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.